4DQM
Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique binding mode and antitumor activity
4DQM の概要
| エントリーDOI | 10.2210/pdb4dqm/pdb |
| 分子名称 | Retinoic acid receptor alpha, Nuclear receptor coactivator 1, (5S)-4-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,7-dien-1-yl]-5-hydroxyfuran-2(5H)-one, ... (4 entities in total) |
| 機能のキーワード | nuclear receptor transcription factor, ligand binding domain, transcription regulation, nucleus, transcription-transferase complex, transcription/transferase |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| 細胞内の位置 | Nucleus: P10276 Q15788 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 56091.71 |
| 構造登録者 | |
| 主引用文献 | Wang, S.,Wang, Z.,Lin, S.,Zheng, W.,Wang, R.,Jin, S.,Chen, J.,Jin, L.,Li, Y. Revealing a natural marine product as a novel agonist for retinoic acid receptors with a unique binding mode and inhibitory effects on cancer cells. Biochem.J., 446:79-87, 2012 Cited by PubMed Abstract: Retinoids display anti-tumour activity on various cancer cells and therefore have been used as important therapeutic agents. However, adverse side effects and RA (retinoic acid) resistance limit further development and clinical application of retinoid-based therapeutic agents. We report in the present paper the identification of a natural marine product that activates RARs (RA receptors) with a chemical structure distinct from retinoids by high-throughput compound library screening. Luffariellolide was uncovered as a novel RAR agonist by inducing co-activator binding to these receptors in vitro, further inhibiting cell growth and regulating RAR target genes in various cancer cells. Structural and molecular studies unravelled a unique binding mode of this natural ligand to RARs with an unexpected covalent modification on the RAR. Functional characterization further revealed that luffariellolide displays chemotherapeutic potentials for overcoming RA resistance in colon cancer cells, suggesting that luffariellolide may represent a unique template for designing novel non-retinoid compounds with advantages over current RA drugs. PubMed: 22642567DOI: 10.1042/BJ20120726 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.75 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






